
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
SATB2 CRISPR/Cas9 KO Plasmid (m) | sc-431818 | 20 µg | $397.00 |
Satb2 encodes SATB2, a nuclear matrix-associated transcriptional regulator that binds AT-rich DNA elements and organizes higher-order chromatin structure to coordinate lineage-specific gene expression programs in mouse cells. SATB2 influences developmental transcriptional networks and epigenetic regulation, impacting processes such as differentiation, tissue patterning, and neuronal maturation through modulation of chromatin accessibility and long-range enhancer–promoter interactions. In the immune system and other tissues, SATB family proteins integrate signaling-dependent transcriptional responses by shaping genome architecture and co-regulator recruitment. Dysregulated SATB2 activity is associated with altered differentiation states and aberrant gene expression signatures relevant to developmental phenotypes and disease-associated transcriptional rewiring.
SATB2 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Satb2 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Satb2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Satb2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish SATB2 protein expression.
This CRISPR knockout system enables efficient generation of Satb2-deficient cell models for investigation of SATB2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
CRISPRs +/- HDRs
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.